Atogepant

Generic Name
Atogepant
Brand Names
Qulipta, Aquipta
Drug Type
Small Molecule
Chemical Formula
C29H23F6N5O3
CAS Number
1374248-81-3
Unique Ingredient Identifier
7CRV8RR151
Background

Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. While its approval was predated by two other members of the same drug family, namely ubrogepant and rimegepant, th...

Indication

Atogepant is indicated for the preventive treatment of migraine in adults by the FDA, EMA, and Health Canada.

Associated Conditions
Episodic Migraine, Migraine
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath